EP0694078A4 - Procede de triage concernant des agonistes de recepteurs - Google Patents

Procede de triage concernant des agonistes de recepteurs

Info

Publication number
EP0694078A4
EP0694078A4 EP94913374A EP94913374A EP0694078A4 EP 0694078 A4 EP0694078 A4 EP 0694078A4 EP 94913374 A EP94913374 A EP 94913374A EP 94913374 A EP94913374 A EP 94913374A EP 0694078 A4 EP0694078 A4 EP 0694078A4
Authority
EP
European Patent Office
Prior art keywords
screening
receptor agonists
agonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94913374A
Other languages
German (de)
English (en)
Other versions
EP0694078A1 (fr
Inventor
Ronald P Mcdonnell
Maty Tzukerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of EP0694078A1 publication Critical patent/EP0694078A1/fr
Publication of EP0694078A4 publication Critical patent/EP0694078A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94913374A 1993-04-07 1994-04-06 Procede de triage concernant des agonistes de recepteurs Withdrawn EP0694078A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4580793A 1993-04-07 1993-04-07
US45807 1993-04-07
US17975094A 1994-01-10 1994-01-10
US179750 1994-01-10
PCT/US1994/003795 WO1994023068A1 (fr) 1993-04-07 1994-04-06 Procede de triage concernant des agonistes de recepteurs

Publications (2)

Publication Number Publication Date
EP0694078A1 EP0694078A1 (fr) 1996-01-31
EP0694078A4 true EP0694078A4 (fr) 1997-06-25

Family

ID=26723218

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94913374A Withdrawn EP0694078A4 (fr) 1993-04-07 1994-04-06 Procede de triage concernant des agonistes de recepteurs

Country Status (6)

Country Link
EP (1) EP0694078A4 (fr)
JP (1) JPH08512197A (fr)
AU (1) AU6556194A (fr)
BR (1) BR9406616A (fr)
CA (1) CA2160135A1 (fr)
WO (1) WO1994023068A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ51897A3 (en) * 1994-08-22 1997-06-11 Lilly Co Eli Inhibition method of endometrial cancer
AU6263996A (en) * 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
EP0788353A1 (fr) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Antagonistes de ppar gamma pour le traitement de l'obesite
US6692928B1 (en) 1996-07-19 2004-02-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular agents
US5728534A (en) * 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents
EP1093362A1 (fr) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
PT1248604E (pt) 2000-01-21 2007-01-31 Novartis Ag Associações compreendendo inibidor de dipeptidilpeptidase-iv
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1388352A1 (fr) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
MXPA06001751A (es) 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
ES2445180T5 (es) 2005-09-14 2022-02-01 Takeda Pharmaceuticals Co Administración de inhibidores de dipeptidil peptidasa
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
ES2445917T3 (es) 2010-02-03 2014-03-06 Takeda Pharmaceutical Company Limited Inhibidores de quinasa 1 reguladora de la señal de apoptosis
US20160263189A1 (en) 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
CA3120970A1 (fr) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Procedes de traitement du metabolisme lipidique deregule

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERRY ET AL.: "Role of the two activating domains of the oestrogen receptor in the cell-type and promotor-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen", EMBO J., vol. 9, no. 9, 1990, pages 2811 - 2818, XP002018774 *
BOCQUEL ET AL.: "the contribution of The n-and c-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific", NUCLEIC.ACIDS RES., vol. 17, 1989, pages 2581 - 2595, XP002018772 *
MCDONNELL ET AL.: "NUCLEAR HORMON RECEPTORS AS TARGETS FOR NEW DRUG DISCOVERY", BIO/TECHNOLOGY, November 1993 (1993-11-01), pages 1256 - 1261, XP002018771 *
See also references of WO9423068A1 *
TORA ET AL.: "The human estrogen receptor has two independent nonacidic transcriptional activation functions", CELL, vol. 59, 3 November 1989 (1989-11-03), pages 477 - 487, XP002018773 *

Also Published As

Publication number Publication date
CA2160135A1 (fr) 1994-10-13
JPH08512197A (ja) 1996-12-24
BR9406616A (pt) 1996-02-06
EP0694078A1 (fr) 1996-01-31
AU6556194A (en) 1994-10-24
WO1994023068A1 (fr) 1994-10-13

Similar Documents

Publication Publication Date Title
EP0871477A4 (fr) Procede d'obtention d'anticorps antagonistes de recepteurs
EP0735358A3 (fr) Dispositif automatique de préparation d'échantillons
GB9303527D0 (en) Network analysis method
GB9125426D0 (en) Method for predicting cement properties
EP0694078A4 (fr) Procede de triage concernant des agonistes de recepteurs
SG47581A1 (en) Receptor identification method
EP0656067A4 (fr) Procedes de depistage d'agents immunosuppressifs.
IL121017A0 (en) Method of screening compounds for LC132 receptor agonist
AU6524794A (en) Cloned receptors and methods for screening
AU6263996A (en) Method for screening for receptor agonists and antagonists
HU9602670D0 (en) Screening method using the rzr receptor family
GB2284054B (en) Method for range determination
GB9322811D0 (en) Screening apparatus
EP0743151A3 (fr) Appareil de fusion
ZA947681B (en) Method for preparing 3-aminopyridines from 3-nitro-pyridines
NZ322838A (en) Method for determining feed quality
GB9310778D0 (en) Screening apparatus
EP0749755A3 (fr) Procédé pour identifier des composés antagonistes des récepteurs RARs
GB2277599B (en) Apparatus for weighing softened solid
EP0786084A4 (fr) Procede destine aux essais de selection de compositions
GB9525703D0 (en) Screening method
GB2306530B (en) Apparatus for use with downhole liners
GB2303563B (en) Screening apparatus
GB2277046B (en) Grading apparatus
GB2300130B (en) Screening apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970506

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001130